No Data
Information on individual stocks.
Chordi<190A.T> has sharply fallen. A notification was received from Ono Pharmaceutical<4528.T>, the licensee of the 'CTX-177 (ONO-7018)', which is an inhibitor of the translocation protein associated with mucosal-related lymphoid tissue lymphoma, stating that development is to be discontinued for strategic reasons, and the rights will be returned to the company. Sea U C<9158.T> declined significantly for the fourth consecutive day, hitting a year-to-date low. The consolidated net profit for the fiscal year ending March 2025 was announced to be 3.131 billion yen (previously
＜Individual stock trends＞ Taiyo HD, Itochu Food, Kawata, Ono Pharmaceutical, Hitachi = 30th afternoon session.
Sun HD <4626.T> - For the fiscal year ending March 2026, consolidated results are expected to show increased revenue and operating profit, with plans to raise Dividends. Itochu Foods <2692.T> - For the fiscal year ending March 2026, plans to increase operating profit by double digits and raise Dividends. Kawata <6292.T> - Upward revision of consolidated profit estimates for the fiscal year ending March 2025. Ono Pharmaceutical <4528.T> - Downward revision of consolidated profit estimates for the fiscal year ending March 2025. Hitachi <6501.T> - For the fiscal year ending March 2026, the consolidated adjusted operating profit (IFRS) is expected to be 1.05 trillion yen, based on a market average forecast of 1.1227 trillion yen.
Chordia --- significantly dropped, development halted for the inhibitor of the mucosal-associated lymphoid tissue lymphoma translocation protein 1.
Significantly declined. It has been announced that the strategic licensing partner, Ono Pharmaceutical Co., Ltd. <4528>, has decided to cease the development of the Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) inhibitor "CTX-177" for strategic reasons and return the rights related to its development, manufacturing, and commercialization to Chordia Therapeutics. Going forward, discussions will be held with Ono Pharmaceutical regarding the termination of the licensing agreement, and options will be considered.
Ono Pharmaceutical Revises Fiscal Year Ended March 31 Estimates
Stable, U.S. stocks are resilient and the buying intent continues.
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to show a solid performance. The Dow Inc average rose by 114.09 dollars (+0.28%) in the US stock market two days ago on the 28th. Expectations for tax cuts and a stable bond market supported stock prices, while uncertainties regarding tariffs and the decline of NVIDIA (NVDA) weighed on them. Yesterday, on the 29th, it increased by 300.03 dollars (+0.75%) to 40,527.62 dollars, marking a sixth consecutive rise. Treasury Secretary Yellen stated that trade negotiations are progressing.
＜Today's individual materials＞ Morpho, Aiming, Kurita, Ono Pharmaceutical, etc. (Announced on the 28th)
▽ Morphō <3653.T> strengthens capital and business alliance with Mickware (Kobe City, Hyōgo Prefecture) ▽ Aiiming <3911.T>, the consolidated earnings report for the first quarter of the fiscal year ending December 2025 (January-March) shows a profit shift ▽ Kurita Water Industries <6370.T> revises its consolidated performance forecast for the fiscal year ending March 2025 downward ▽ Ono Pharmaceutical <4528.T> lowers its consolidated profit forecast for the fiscal year ending March 2025 ▽ SMS <2175.T> announces earnings reports and treasury stock acquisition ▽ Kikkoman <2801.T> announces earnings reports, an increase in dividends, and self.
